#Alzheimer #Genetics #Neurodegeneration #PrecisionMedicine #GWAS #MultiAncestral
Alzheimer’s disease (AD) is the
most common form of dementia, affecting
millions worldwide. It is characterized by a progressive decline in cognitive
functions, impacting memory, language, and spatial orientation. While
environmental factors and lifestyle contribute to its onset, genetics play a
crucial role in disease predisposition. It is estimated that 70% to 80% of the
risk of developing AD is hereditary, highlighting the importance of identifying
the genes involved to better understand the pathology and develop targeted
therapeutic approaches.
Genome-wide
association studies (GWAS), which detect genetic variations
linked to AD, have so far been predominantly conducted on
populations of
European ancestry. This limitation presents several challenges: some genetic
markers are prioritized, while
variants potentially specific to other ethnic
groups remain overlooked. AD incidence and clinical manifestations can vary
across populations, suggesting different genetic influences.
The
underrepresentation of non-European populations prevents a
comprehensive understanding of
genetic risk factors and hinders the development
of
screening and treatment strategies tailored to all patients. An incomplete
genetic picture of AD reduces researchers’ ability to
develop reliable
biomarkers and effective
personalized treatments for diverse communities.
Addressing these challenges requires integrating
more diverse cohorts into
genetic research to
identify universal and population-specific therapeutic
targets.
Alzheimer’s disease: are new clues hidden in our genes?
Four major international cohorts (NIAGADS, NIMH, UK Biobank, and All of
Us), including a total of
49,149 cases of Alzheimer’s disease (AD), were
selected. Among them,
12,074 patients were clinically diagnosed, and
37,075
were identified through family proxy reports. A total of 383,225 patients were
selected as controls.
Through
whole-genome sequencing (WGS), researchers studied the
influence
of genetic diversity on Alzheimer’s disease risk, incorporating underrepresented populations from previous studies.
In this study,
16 new loci were associated with AD. Fourteen were
identified in clinically diagnosed patients (five common variants and nine rare
variants), and
two were detected only in proxy cases. These loci play a key
role in essential biological functions such as
neuroplasticity,
neuronal
communication, and
inflammatory response. Their involvement suggests a direct
link with the
underlying mechanisms of Alzheimer’s disease.
A
low overlap was observed between loci associated with clinically
diagnosed cases and those identified in proxy cases. This discrepancy suggests
that
family history alone is not a reliable indicator of genetic mechanisms,
especially in
genetically diverse populations. These findings emphasize the
need to
refine genetic classification criteria and
conduct further research on
hereditary mechanisms in AD through more inclusive population-based analyses.
Read next: Alzheimer’s Disease: The Amyloid Hypothesis Is Not the Only Factor
A future without Alzheimer’s thanks to genetics?
Alzheimer’s disease is a neurodegenerative disorder where
genetics plays
a critical role in individual risk. Identifying these
genetic factors is
essential for improving
diagnosis, prevention, and treatment strategies.
However, a major challenge remains—the
lack of diversity in genetic studies,
which overwhelmingly focus on European populations. This underrepresentation
limits the understanding of
risk factors and slows down the development of
treatments for all individuals.
This study explores the impact of
genetic diversity on AD risk,
conducting a large-scale multi-ancestral genome-wide analysis. The findings
identified 16 novel AD-associated loci, providing new insights into the
disease’s underlying mechanisms. These discoveries reinforce the importance of a
more inclusive genetic approach to refine prevention and treatment strategies.
Despite its strengths, the study presents
some limitations, including
data heterogeneity and the difficulty of
validating certain loci across
different cohorts. Additionally, the differences between
clinically diagnosed
cases and proxy cases highlight the need to
refine AD’s genetic criteria.
Moving forward,
integrating whole-genome sequencing could enhance
early
diagnosis and pave the way for
personalized treatments. Expanding
cohorts and
improving
genetic models will be essential to translate these discoveries into
clinical
applications.
Read next: Predicting Amyloid: AI for Early Detection
